Less Than Half Of ODAC Members Will Participate In Avastin Hearing
The "jury" for FDA's June 28-29 hearing on Avastin's breast cancer indication will consist of only six voting participants, five of whom previously called for the claim's withdrawal.
The "jury" for FDA's June 28-29 hearing on Avastin's breast cancer indication will consist of only six voting participants, five of whom previously called for the claim's withdrawal.